cjc-1295 with ipamorelin benefits CJC-1295/Ipamorelin General Info Sheet CJC-1295 + Ipamorelin - Beverly
Description
In a phase I trial in patients with advanced solid tumors, treatment with the IGF-1R/INSR TKI linsitinib in combination with erlotinib was well tolerated, with preliminary evidence of clinical activity, particularly in patients with NSCLC
10.4161/cc.7.24.7231
Hakeem, A
Deletion of mprA/B and pepD genes resulted in 83.593.2% and 52.160.6% respective reductions in pls transcription and -PL production (Pan et al., 2019b)
This enzyme appears to have context-dependent functions across different cancer types
